Angiodynamics Inc. (ANGO)
Down 25.0% in 4 Weeks, Here's Why You Should You Buy the Dip in AngioDynamics (ANGO)
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ANGO Stock Dips Despite Q2 Earnings Beat, Gross Margin Improves
AngioDynamics reports flat Q2 earnings while revenue increase 8.8% and gross margin expands 170 bps on stronger Med Tech performance.
AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript
AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript
AngioDynamics: Growth Remains Under The Radar
AngioDynamics looks undervalued, with Med Tech segment growth in thrombus management, atherectomy, and NanoKnife driving the investment thesis. Consistent execution on revenue growth and margin improvement, especially in Med Tech, is critical for rerating; legacy Med Device business remains a headwind to sentiment. Recent clinical data for AlphaVac and NanoKnife support further adoption, while Auryon continues steady share gains in a competitive atherectomy market.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves
AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.
AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO ) Q1 2026 Earnings Call October 2, 2025 8:00 AM EDT Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference Call Participants John Young - Canaccord Genuity Corp., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2026 First Quarter Earnings Call.
AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.11 per share a year ago.
Wall Street Week Ahead
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones, and a balanced portfolio despite tariff headwinds.
AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul
AngioDynamics has completed a strategic transformation, divesting non-core assets and focusing on high-growth MedTech platforms, driving accelerating revenue and margin improvement. Recent results confirm an inflection point: MedTech sales grew 19.5% in FY25, adjusted EBITDA turned positive, and the company now boasts a strong net cash balance sheet. Favorable sector trends, regulatory wins, and unique product positioning (Auryon, AlphaVac, NanoKnife) underpin robust growth prospects and expanding addressable markets.
